CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, announced that encouraging clinical findings with the TAP compound, AVE9633, were reported today at the American Society of Hematology (ASH) 49th Annual Meeting and Exposition. AVE9633 demonstrated evidence of biological activity in multiple patients with relapsed/refractory acute myeloid leukemia (AML) and was found to be generally well tolerated. Highly favorable preclinical findings also were reported for SAR3419, a TAP compound now in clinical testing for the treatment of non-Hodgkin’s lymphoma and other B-cell malignancies.
